Literature DB >> 18772135

Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein.

Vanda Bartonova1, Sébastien Igonet, Jana Sticht, Bärbel Glass, Anja Habermann, Marie-Christine Vaney, Peter Sehr, Joe Lewis, Felix A Rey, Hans-Georg Kraüsslich.   

Abstract

Morphogenesis of infectious HIV-1 involves budding of immature virions followed by proteolytic disassembly of the Gag protein shell and subsequent assembly of processed capsid proteins (CA) into the mature HIV-1 core. The dimeric interface between C-terminal domains of CA (C-CA) has been shown to be important for both immature and mature assemblies. We previously reported a CA-binding peptide (CAI) that blocks both assembly steps in vitro. The three-dimensional structure of the C-CA/CAI complex revealed an allosteric effect of CAI that alters the C-CA dimer interface. Based on this structure, we now investigated the phenotypes of mutations in the binding pocket. CA variants carrying mutations Y169A, L211A, or L211S had a reduced affinity for CAI and were unable to form mature-like particles in vitro. These mutations also blocked morphological conversion to mature virions in tissue culture and abolished infectivity. X-ray crystallographic analyses of the variant C-CA domains revealed that these alterations induced the same allosteric change at the dimer interface observed in the C-CA/CAI complex. These results point to a role of key interactions between conserved amino acids in the CAI binding pocket of C-CA in maintaining the correct conformation necessary for mature core assembly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772135     DOI: 10.1074/jbc.M804230200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution.

Authors:  Florian K M Schur; Wim J H Hagen; Michaela Rumlová; Tomáš Ruml; Barbara Müller; Hans-Georg Kräusslich; John A G Briggs
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

2.  Structure of the immature retroviral capsid at 8 Å resolution by cryo-electron microscopy.

Authors:  Tanmay A M Bharat; Norman E Davey; Pavel Ulbrich; James D Riches; Alex de Marco; Michaela Rumlova; Carsten Sachse; Tomas Ruml; John A G Briggs
Journal:  Nature       Date:  2012-07-19       Impact factor: 49.962

Review 3.  HIV-1 assembly, budding, and maturation.

Authors:  Wesley I Sundquist; Hans-Georg Kräusslich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

4.  Hydrogen/deuterium exchange analysis of HIV-1 capsid assembly and maturation.

Authors:  Eric B Monroe; Sebyung Kang; Sampson K Kyere; Rui Li; Peter E Prevelige
Journal:  Structure       Date:  2010-11-10       Impact factor: 5.006

5.  On the accuracy of unit-cell parameters in protein crystallography.

Authors:  Zbigniew Dauter; Alexander Wlodawer
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2015-10-31

6.  Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Mol Interv       Date:  2009-04

7.  Structural and dynamical characterization of tubular HIV-1 capsid protein assemblies by solid state nuclear magnetic resonance and electron microscopy.

Authors:  Bo Chen; Robert Tycko
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

8.  Structure and assembly of immature HIV.

Authors:  J A G Briggs; J D Riches; B Glass; V Bartonova; G Zanetti; H-G Kräusslich
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

Review 9.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 10.  HIV-1 Capsid Inhibitors as Antiretroviral Agents.

Authors:  Suzie Thenin-Houssier; Susana T Valente
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.